MARKET COMPOSITE
Market TodayThemes and Stocks SummaryThematic Stock SearchFAQAbout
Home/
CSBR - Champions Oncology Inc
Price
$0.00
+ 0.00 (0.00%)
Champions Oncology, Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The company, through its Tumorgraft Technology Platform, provides Personalized Oncology Solutions (POS) that assist physicians in developing personalized treatment options for cancer patients through tumor specific data obtained from drug panels and related personalized oncology services. It also offers Translational Oncology Solutions that utilizes its technology platform to assist pharmaceutical and biotechnology companies with their drug development process. In addition, the company provides POS products, including TumorGraft implants and drug panels, which utilizes TumorGraft technology to test the response of a patient's tumor to multiple oncology drugs or drug combinations. It markets its products through internet, word of mouth, and sales force to patients and physicians. The company was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011. Champions Oncology, Inc. was incorporated in 1985 and is headquartered in Hackensack, New Jersey.
Financials
Quarterly financials
(USD)Oct 2023Q/Q
Revenue11.6MM-8%
Gross Profit5MM-
Cost Of Revenue6.6MM-14%
Operating Income-2MM-23%
Operating Expenses6.9MM-
Net Income-2.1MM-19%
R&D2.5MM-10%
G&A2.6MM-12%
Marketing1.8MM+6%
Stock Chart

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 

Finra

Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

Related
Topics
Biotechnology-1.70%
leak data
Stock news

Load more